Methimazole-Induced Bullous Systemic Lupus Erythematosus: A Case Report.
10.3346/jkms.2012.27.7.818
- Author:
Ji Yeon SEO
1
;
Hee Jin BYUN
;
Kwang Hyun CHO
;
Eun Bong LEE
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. leb7616@snu.ac.kr
- Publication Type:Case Reports
- Keywords:
Bullous Systemic Lupus Erythematosus;
Drug-Induced Lupus Erythematosus;
Methimazole;
Graves Disease
- MeSH:
Adult;
Anti-Inflammatory Agents/therapeutic use;
Antirheumatic Agents/therapeutic use;
Antithyroid Agents/*adverse effects/therapeutic use;
Blister/chemically induced/pathology;
Drug Therapy, Combination;
Female;
Graves Disease/diagnosis/drug therapy;
Humans;
Hydroxychloroquine/therapeutic use;
Immunosuppressive Agents/therapeutic use;
Lupus Erythematosus, Systemic/chemically induced/*diagnosis/drug therapy;
Lupus Nephritis/diagnosis/drug therapy;
Methimazole/*adverse effects/therapeutic use;
Mycophenolic Acid/analogs & derivatives/therapeutic use;
Prednisolone/therapeutic use;
Skin/pathology
- From:Journal of Korean Medical Science
2012;27(7):818-821
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bullous systemic lupus erythematosus (SLE) is a kind of LE-non-specific bullous skin disease that is rarely induced by a medication. We describe the first case of bullous SLE to develop after administration of methimazole. A 31-yr-old woman presented with generalized erythematous patches, multiple bullae, arthralgia, fever, conjunctivitis, and hemolytic anemia. Biopsy of her bulla showed linear deposition of lgG, lgA, C3, fibrinogen, and C1q at dermo-epidermal junction. She was diagnosed as bullous SLE and treated with prednisolone, dapsone, hydroxychloroquine, and methotrexate. Our experience suggests that SLE should be considered as a differential diagnosis when bullous skin lesions develop in patients being treated for hyperthyroidism.
